Abuse liability assessment of anxiolytics/ hypnotics: rationale and laboratory lore

Wiley - Tập 86 Số 12 - Trang 1625-1632 - 1991
Suzette M. Evans1, Thomas S. Critchfield1, Roland R. Griffiths2,1
1Department of Psychiatry and Behavioral Sciences, Baltimore, Maryland, USA
2Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Tóm tắt

AbstractThis paper describes the rationale, practical details, and laboratory lore relevant to conducting an acute dose‐effect crossover evaluation for abuse liability of a novel anxiolytic/hypnotic compound relative to a standard compound. Basic principles underlying meaningful abuse liability assessments are presented and illustrated with examples from a comparative evaluation of the hypnotics zolpidem and triazolam. These principles include using a double‐blind placebo‐controlled design, selecting an appropriate comparison compound, evaluating a wide range of doses including supratherapeutic doses, using subjects with histories of sedative drug abuse, and using a range of dependent measures. The dose‐effect crossover evaluation is proposed as a crucial first step in any rigorous drug abuse liability evaluation of a novel anxiolytic or hypnotic drug. Such a study can be expected to generate a broad data base which not only provides a prediction about the likelihood of abuse of the novel compound, but provides an assessment of some of the adverse consequences of recreational abuse. The crossover study also establishes parameters for subsequent studies such as direct assessment of reinforcing effects with drug self‐administration testing.

Từ khóa


Tài liệu tham khảo

10.1007/978-1-4615-7743-0_2

10.1016/0376-8716(91)90054-3

10.1007/BF00431805

Evans S. M., 1990, Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability, Journal of Pharmacology and Experimental Therapeutics, 255, 1246

Fraser H. F., 1977, Drug Addiction I. Morphine, Sedative‐Hypnotic and Alcohol Dependence, Handbook of Experimental Pharmacology, 159

Haertzen C. A., 1974, An Overview of Addiction Research Center Inventory Scales (ARCI): An Appendix and Manual of Scales, 74

10.1002/cpt196892215

10.1097/00004714-199006000-00002

McNair D., 1971, Profile of Mood states (Manual)

Morselli P. L., 1988, Imidazopyridines in Sleep Disorders, 183

10.1111/j.1365-2125.1986.tb05176.x

Preston K. L., 1989, Evaluation of the abuse potential of methocarbamol, Journal of Pharmacology and Experimental Therapeutics, 248, 1146

Roache J. D., 1985, Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability, Journal of Pharmacology and Experimental Therapeutics, 234, 120

10.1016/0376-8716(86)90032-3

Roache J. D., 1987, Lorazepam and meprobamate dose effects in humans: Behavioral effects and abuse liability, Journal of Pharmacology and Experimental Therapeutics, 243, 978

Roache J. D., 1989, Testing for abuse liability of drugs, 123

10.1007/BF00445549

Thông tin
Thông tin xuất bản

Wiley

Tập 86 Số 12

1625-1632

Thông tin tác giả